The Centers for Medicare & Medicaid Services (CMS) is developing a pilot program that could change the landscape of obesity ...

Trump demands U.S. drug prices match lowest international rates for some or face executive action. This article originally ...

Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.

Medicare Advantage usage trends reveal slight declines in 2023, highlighting critical insights for policymakers amid rising ...

Eli Lilly's stock is lagging the S&P 500 since April, potentially allowing a catch-up trade if results impress. Medicare may ...

With approximately 60% of prescription drugs coming from Europe, including major brands like Ozempic, Botox and Eliquis, many ...

GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...

President Donald Trump says pharma tariffs could go as high as 250%. UBS downgrades Novo Nordisk stock to neutral and lowers ...

Relief is coming for more than 5 million Medicare beneficiaries who rely on expensive prescription medications.

The Center for Medicare and Medicaid Innovation may introduce a five-year pilot model to expand access to weight loss drugs, ...

Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.

Earlier this year, the Centers for Medicare and Medicaid Services scrapped a previous proposal, from the Biden administration ...